scholarly journals Pleural plaques in smoking-associated fibrosis and pulmonary asbestosis

Author(s):  
Rahul Sangani ◽  
Andrew Ghio ◽  
John Parker
1997 ◽  
Vol 6 (2) ◽  
pp. 100-105 ◽  
Author(s):  
Yalçin Karakoca ◽  
Salih Emri ◽  
Ayten Kayi Cangir ◽  
Yusuf Izzettin Baris
Keyword(s):  

1997 ◽  
Vol 6 (2) ◽  
pp. 69-71 ◽  
Author(s):  
John A. Hoskins
Keyword(s):  

2016 ◽  
Vol 28 (11) ◽  
pp. 514-519 ◽  
Author(s):  
Ke Zu ◽  
Ge Tao ◽  
Julie E. Goodman

2016 ◽  
Vol 150 ◽  
pp. 23-29 ◽  
Author(s):  
Caterina Ledda ◽  
Cristoforo Pomara ◽  
Massimo Bracci ◽  
Dario Mangano ◽  
Vincenzo Ricceri ◽  
...  

2018 ◽  
Vol 2018 ◽  
pp. 1-3
Author(s):  
Adam Dallmann ◽  
Richard L. Attanoos

Yellow nail syndrome is a rare acquired condition of unknown aetiology associated with distinct nail discolouration/xanthonychia, pulmonary manifestations, and lymphoedema. Pleural plaques and diffuse pleural thickening are typically, although not exclusively, recognised as markers of prior commercial asbestos exposure. The presence of such biomarkers may assist an asbestos personal injury evaluation. A postmortem examination performed on a 72-year-old man with known long-standing yellow nail syndrome identified pleural plaques and diffuse pleural thickening. An evaluation of the occupational history identified no known asbestos exposure. Electron microscopic mineral fibre analysis detected no asbestos fibres. To the best of our knowledge, this is the only case of yellow nail syndrome in which these benign pleural changes are reported ex asbestos. Alternate causes for such pleural pathology were absent. There is merit in physicians and pathologists having an awareness of these new manifestations when considering claimed asbestos related changes during life and at postmortem.


2017 ◽  
Vol 2017 ◽  
pp. 1-8 ◽  
Author(s):  
Zhaoqiang Jiang ◽  
Shibo Ying ◽  
Wei Shen ◽  
Xianglei He ◽  
Junqiang Chen ◽  
...  

Fibulin-3 has been reported as a potential biomarker for mesothelioma. However, little is known about the diagnostic efficacies of fibulin-3 for asbestos-related diseases (ARDs) in China. This study was to investigate the utility of fibulin-3 for asbestos exposure and ARDs. A total of 430 subjects were recruited from Southeast China, including healthy individuals, asbestos-exposed (AE) individuals, and patients with pleural plaques (PP), asbestosis, and malignant pleural mesothelioma (MPM). Plasma fibulin-3 was measured using the enzyme-linked immunosorbent assay. Linear regression analyses were applied to explore the influencing factors of fibulin-3. Receiver operating characteristic curves were used to determine the cutoff values. The median fibulin-3 level of subjects in the mesothelioma group was higher than that in other groups. Subjects in the asbestosis group had higher median fibulin-3 level than those in the control group. A higher fibulin-3 level was found in the group with ≥10 years of asbestos exposure as compared with control groups. The AUCs of fibulin-3 for distinguishing MPM subjects from control, AE, PP, and asbestosis subjects were 0.92, 0.88, 0.90, and 0.81, respectively. Our study provided evidence that fibulin-3 could be a potential biomarker for the early screening of MPM, but not of other nonmalignant ARDs in Chinese populations.


Radiology ◽  
1981 ◽  
Vol 140 (3) ◽  
pp. 634-634 ◽  
Author(s):  
E N Sargent ◽  
J S Felton ◽  
L T Barnes

Sign in / Sign up

Export Citation Format

Share Document